Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-13
DOI
10.1186/s12885-020-07374-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Projected estimates of cancer in Canada in 2020
- (2020) Darren R. Brenner et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review
- (2019) Adam J. N. Raymakers et al. CANCER
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of costs associated with adverse events in patients with cancer
- (2018) William Wong et al. PLoS One
- Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
- (2018) Satish Shanbhag et al. EUROPEAN JOURNAL OF CANCER
- Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
- (2018) Scott F. Huntington et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma
- (2018) Thomas E. Delea et al. JOURNAL OF MEDICAL ECONOMICS
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- flexsurv: A Platform for Parametric Survival Modeling inR
- (2016) Christopher Jackson Journal of Statistical Software
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
- (2015) Andres Forero-Torres et al. BLOOD
- Treatment of Hodgkin Lymphoma: A 50-Year Perspective
- (2014) George P. Canellos et al. JOURNAL OF CLINICAL ONCOLOGY
- Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2014) Paul Swinburn et al. LEUKEMIA & LYMPHOMA
- Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study
- (2012) H. M. Blommestein et al. ANNALS OF HEMATOLOGY
- Brentuximab vedotin in Hodgkin's lymphoma
- (2012) Barbara Pro et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
- (2011) Christian Steidl et al. JOURNAL OF CLINICAL ONCOLOGY
- ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
- (2011) Simonetta Viviani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy
- (2010) Juliano J. Cerci et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now